Sarcopenia and Risk of Falls in Patients With Major Chronic Diseases

Sponsor
Changhua Christian Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT03798418
Collaborator
(none)
320
1
2
41.9
7.6

Study Details

Study Description

Brief Summary

The objective of this study is to investigate the effects of therapeutic exercise and nutrition intervention for sarcopenia and risk of falls in patients with major chronic diseases. The outcomes will be analyzed regarding muscle strength, quality, and volume, etc., balance and gait, bone density, body composition, fall and quality of life after the intervention.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: elastic band strengthening exercise
  • Dietary Supplement: diet counseling
N/A

Detailed Description

The main common chronic diseases in the elderly such as stroke, osteoporosis, chronic kidney disease and cancer, have been regarded as the fall high-risk patients. These patients are considered to be at risk for sarcopenia due to decreased exercise, nutritional status, and other reasons. Sarcopenia can be diagnosed and intervened effectively to delay the vicious cycle of health. Past studies have pointed out that in addition to drug intervention, treatment for sarcopenia must be accompanied by appropriate exercise and nutritional intervention (such as protein supplements, vitamin D) in order to achieve the best prevention and treatment.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
320 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Outcomes Assessor)
Primary Purpose:
Prevention
Official Title:
Sarcopenia and Risk of Falls in Patients With Major Chronic Diseases - Effects of Therapeutic Exercise and Nutrition Intervention
Actual Study Start Date :
Feb 1, 2019
Anticipated Primary Completion Date :
Jun 30, 2022
Anticipated Study Completion Date :
Jul 31, 2022

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: exercise group

elastic band strengthening exercise

Behavioral: elastic band strengthening exercise
2-3days per week(150min per week)
Other Names:
  • thera-band strengthening exercise
  • Experimental: exercise combine diet counseling group

    elastic band strengthening exercise combined diet counseling.

    Behavioral: elastic band strengthening exercise
    2-3days per week(150min per week)
    Other Names:
  • thera-band strengthening exercise
  • Dietary Supplement: diet counseling
    each patients in this group will receive4-5times diet counseling
    Other Names:
  • nutrition counseling
  • Outcome Measures

    Primary Outcome Measures

    1. Change of walking speed [baseline: before intervention; follow-up: 3 months after intervention]

      distance: 6m, patients can walk with foor orthosis and assistive devices

    2. Change of grip force [before intervention; follow-up: 3 months after intervention]

      Use a grip force meter (kg) to test both hands for test 3 times

    3. Change of postural sway displacement [before intervention; follow-up: 3 months after intervention]

      Use computerized dynography to measure the postural sway displacement (mm)

    4. Change of postural sway velocity [before intervention; follow-up: 3 months after intervention]

      Use computerized dynography to measure the postural sway velocity (mm/s)

    5. Change of postural sway area [before intervention; follow-up: 3 months after intervention]

      Use computerized dynography to measure the postural sway area (mm^2)

    6. Change of step time [before intervention; follow-up: 3 months after intervention]

      Use computerized dynography to measure spatial gait parameter: step time (ms)

    7. Change of stance time [before intervention; follow-up: 3 months after intervention]

      Use computerized dynography to measure spatial gait parameter: stance time (ms)

    8. Change of swing time [before intervention; follow-up: 3 months after intervention]

      Use computerized dynography to measure spatial gait parameter: swing time (ms)

    9. Change of single support time [before intervention; follow-up: 3 months after intervention]

      Use computerized dynography to measure spatial gait parameter: single support time (ms)

    10. Change of double support time [before intervention; follow-up: 3 months after intervention]

      Use computerized dynography to measure spatial gait parameter: double support time (ms)

    11. Change of step length [before intervention; follow-up: 3 months after intervention]

      Use computerized dynography to measure spatial gait parameter: step distance (mm)

    12. Change of stance length [before intervention; follow-up: 3 months after intervention]

      Use computerized dynography to measure spatial gait parameter: stance distance (mm)

    13. Change of muscle thickness [before intervention; follow-up: 3 months after intervention]

      Use ultrasound to assess muscles morphological parameter: thickness (mm). Target muscles include quadriceps, hamstring, anterior tibialis, gastrocnemius.

    14. Change of muscle fiber length [before intervention; follow-up: 3 months after intervention]

      Use ultrasound to assess muscles morphological parameter: fiber length (mm). Target muscles include quadriceps, hamstring, anterior tibialis, gastrocnemius.

    15. Change of muscle fiber orientation angle [before intervention; follow-up: 3 months after intervention]

      Use ultrasound to assess muscles morphological parameter: fiber orientation angle (degrees). Target muscles include quadriceps, hamstring, anterior tibialis, gastrocnemius.

    16. Change of muscle cross section area [before intervention; follow-up: 3 months after intervention]

      Use ultrasound to assess muscles morphological parameter: cross-sectional area (mm^2). Target muscles include quadriceps, hamstring, anterior tibialis, gastrocnemius.

    17. Change of physiological cost index (PCI) [before intervention; follow-up: 3 months after intervention]

      Heart rate (HR: beats/min) and walking speed (m/s) have been previously shown to be linearly related to oxygen uptake at sub-maximal exercise levels. Combination of these two parameters yields a single value in beats per meter, the physiological cost index (PCI). This is calculated as Working HR - Resting HR (beats/min) / Walking speed (m/s)

    18. Change of international Quality of Life Assessment Short Form -36 (SF-36) [before intervention; follow-up: 3 months after intervention]

      including 8 health concepts: (1) physical functioning, (2) role limitations because of physical health problems; (3) bodily pain, (4) social functioning, (5) general mental health (psychological distress and psychological wellbeing), (6) role limitations because of emotional problems, (7) vitality (energy/fatigue), (8) general health perceptions. Scoring: answers to each question are scored which are then summed and transformed to a 0 - 100 scale. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.

    19. Change of amplitude of Muscle activity [before intervention; follow-up: 3 months after intervention]

      use electromyography to measure the muscles activity in microvolts (uv) included quadriceps, hamstrings, tibialis anterior, gastrocnemius during subject walking in self-selected speed in 6 meters.

    Secondary Outcome Measures

    1. Change of concentration of CRP (C-Reactive Protein) [before intervention; follow-up: 3 months after intervention]

      The concentration of CRP in the blood test. CRP is used mainly as a marker of inflammation.

    2. Change of concentration of ALB (Serum albumin) [before intervention; follow-up: 3 months after intervention]

      The concentration of ALB in the blood test. Albumin is the most important contributor to the maintenance of plasma colloid oncotic pressure; deficiency results in edema.

    3. Change of concentration of Glomerular Filtration Rate (GFR) [before intervention; follow-up: 3 months after intervention]

      The concentration of GFR in the blood test. The glomerular filtration rate is the best test to measure the patient's level of kidney function and determine the stage of kidney disease. It can calculate it from the results of the blood creatinine test.

    4. Change of concentration of Hemoglobin (Hb) [Time Frame: before intervention; follow-up: 3 months after intervention]

      The concentration of Hb in the blood test.

    5. Change of concentration of Glucose SPOT [Time Frame: before intervention; follow-up: 3 months after intervention]

      The concentration of Glucose SPOT in the blood test. TheSpot glucose measurement in epidermal interstitial fluid appears to be a promising alternative to capillary blood glucose estimation

    6. Change of concentration of Cholesterol [before intervention; follow-up: 3 months after intervention]

      The concentration of Cholesterol in the blood test.

    7. Change of concentration of Triglyceride [before intervention; follow-up: 3 months after intervention]

      The concentration of Triglyceride in the blood test.

    8. Change of concentration of Transferrin [before intervention; follow-up: 3 months after intervention]

      The concentration of Transferrin in the blood test.

    9. Change of Berg balance test (BBS) [before intervention; follow-up: 3 months after intervention]

      including 14 items which are scored on a 5 points scale (0-4). The degree of success in achieving each task is given a score of zero (unable) to four (independent), and the final measure is the sum of all of the scores. The item scores are summed, minimum score =0, maximum score = 56

    10. Change of Fugl-Meyer Assessment (FMA) [before intervention; follow-up: 3 months after intervention]

      Items are scored on a 3-point ordinal scale (0 = cannot perform; 1 = performs partially; 2 = performs fully) Maximum Score = 226 points The 5 domains assessed include, Motor function (UE maximum score = 66; LE maximum score = 34), Sensory function (maximum score = 24), Balance (maximum score = 14), Joint range of motion (maximum score = 44), Joint pain (maximum score = 44)

    11. Change of Body Mass Index (BMI) [before intervention; follow-up: 3 months after intervention]

      (body weight) kg/(height) m*(height)m

    12. Change of Mini-mental state examination (MMSE) [before intervention; follow-up: 3 months after intervention]

      It is an 11-question measure that tests five areas of cognitive function: orientation, registration, attention and calculation, recall, and language. The maximum score is 30. A score of 23 or lower is indicative of cognitive impairment.

    13. Change of Modified Ashworth scale (MAS) [before intervention; follow-up: 3 months after intervention]

      measures resistance during passive soft-tissue stretching, the score is ranged from 0-4 0: No increase in muscle tone Slight increase in muscle tone, manifested by a catch and release or by minimal resistance at the end of the range of motion when the affected part(s) is moved in flexion or extension 1+: Slight increase in muscle tone, manifested by a catch, followed by minimal resistance throughout the remainder (less than half) of the ROM More marked increase in muscle tone through most of the ROM, but affected part(s) easily moved Considerable increase in muscle tone, passive movement difficult Affected part(s) rigid in flexion or extension

    14. Change of Muscle tone [before intervention; follow-up: 3 months after intervention]

      measure the muscle tone (kg/m) under muscle resting. Target muscles are quadricep, hamstring, anterior tibialis, gastrocnemius.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    • Inclusion Criteria:
    1. 55-85 years old

    2. 3-6 months after onset

    3. walk independently for at least 10m

    • Exclusion Criteria:
    1. lower limb Brunnstrom stage >5

    2. combine other neuropathy diseases

    3. significant deformity of lower limb include: Modified Ashworth scale(MAS) >3; contracture, fracture, chronic joint pain.

    4. joint arthroplasty

    5. unstable vital sign

    6. can not cooperate study

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Changhua Christian Hospital Changhua Taiwan 500

    Sponsors and Collaborators

    • Changhua Christian Hospital

    Investigators

    • Study Director: Tasen Wei, Doctor, Changhua Christian Hospital

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Ta-Sen Wei,MD, Director, Physical Medical and Rehabilitation, Principal Investigator, Clinical Professor, Changhua Christian Hospital
    ClinicalTrials.gov Identifier:
    NCT03798418
    Other Study ID Numbers:
    • CCH-170208
    First Posted:
    Jan 10, 2019
    Last Update Posted:
    Jul 1, 2021
    Last Verified:
    Jun 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Ta-Sen Wei,MD, Director, Physical Medical and Rehabilitation, Principal Investigator, Clinical Professor, Changhua Christian Hospital
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jul 1, 2021